Bilibili's IndexTTS-2.5 Refines Zero-Shot Voice Cloning
The latest text-to-speech model from bilibili's Index team pairs voice cloning with emotion control across Chinese, English, and Japanese.
Bilibili's Index team has published IndexTTS-2.5, the newest iteration of its text-to-speech system on Hugging Face. The model targets zero-shot voice cloning, meaning it can reproduce a speaker's voice from a short reference sample without task-specific fine-tuning.
Beyond straightforward cloning, IndexTTS-2.5 offers emotion control and cross-lingual synthesis. According to the release, it supports Chinese, English, and Japanese, positioning it for use cases that span dubbing, localization, and expressive narration.
Why it matters
Zero-shot cloning with emotion steering has become a competitive frontier in open speech models, and multilingual coverage is what separates a demo from a production tool. A few practical implications:
- Creators can generate voiceovers in three major languages from a single reference clip.
- Emotion control gives finer editorial command over tone without re-recording.
- Coming from bilibili, a large video platform, the model reflects real content-production demands.
The model ships under a custom license, so teams evaluating it for commercial work should review the terms on the model page before deploying. As a point release in the IndexTTS line, version 2.5 signals steady, incremental progress rather than a ground-up redesign.
Sources
- Visit
IndexTeam/IndexTTS-2.5
Hugging Face
More in Text → Speech
NVIDIA opens Magpie TTS for multilingual voice agents
The company releases open weights for a low-latency, multilingual text-to-speech model aimed at real-time conversational systems.
NVIDIA Opens Magpie TTS for Multilingual Voice Agents
The open-weights text-to-speech model targets low-latency, deployable voice agents across multiple languages.

NVIDIA's Nemotron VoiceChat 11B Targets Spoken AI
An 11-billion-parameter voice conversation model built atop Nemotron Nano 9B v2 arrives on Hugging Face.
0 comments
No comments yet. Be the first to weigh in.